IL292882A - Dosage of Bruton's tyrosine kinase inhibitor - Google Patents
Dosage of Bruton's tyrosine kinase inhibitorInfo
- Publication number
- IL292882A IL292882A IL292882A IL29288222A IL292882A IL 292882 A IL292882 A IL 292882A IL 292882 A IL292882 A IL 292882A IL 29288222 A IL29288222 A IL 29288222A IL 292882 A IL292882 A IL 292882A
- Authority
- IL
- Israel
- Prior art keywords
- salt
- compound
- use according
- dose
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944674P | 2019-12-06 | 2019-12-06 | |
| US202063077996P | 2020-09-14 | 2020-09-14 | |
| US202063109698P | 2020-11-04 | 2020-11-04 | |
| PCT/US2020/063089 WO2021113497A1 (en) | 2019-12-06 | 2020-12-03 | Dosing of a bruton's tyrosine kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL292882A true IL292882A (en) | 2022-07-01 |
Family
ID=73854977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL292882A IL292882A (en) | 2019-12-06 | 2020-12-03 | Dosage of Bruton's tyrosine kinase inhibitor |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230041515A1 (enExample) |
| EP (1) | EP4069219A1 (enExample) |
| JP (3) | JP7142173B2 (enExample) |
| KR (2) | KR20230127372A (enExample) |
| CN (1) | CN115175677A (enExample) |
| AU (2) | AU2020397034B2 (enExample) |
| BR (1) | BR112022009716A2 (enExample) |
| IL (1) | IL292882A (enExample) |
| MX (1) | MX2022006631A (enExample) |
| WO (1) | WO2021113497A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3224945C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380907B (es) * | 2015-12-16 | 2025-03-12 | Loxo Oncology Inc | Compuestos útiles como inhibidores de cinasa. |
| WO2017132474A1 (en) | 2016-01-30 | 2017-08-03 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| LT3494115T (lt) | 2016-08-05 | 2021-01-25 | The Regents Of The University Of Michigan | N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai |
| WO2018127130A1 (en) | 2017-01-07 | 2018-07-12 | Shanghai Fochon Pharmaceutical Co., Ltd. | Compounds as bcl-2-selective apoptosis-inducing agents |
| PT3612531T (pt) * | 2017-04-18 | 2022-10-04 | Shanghai Fochon Pharmaceutical Co Ltd | Agentes indutores de apoptose |
| WO2019020606A1 (en) * | 2017-07-26 | 2019-01-31 | F. Hoffmann-La Roche Ag | POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY |
| WO2019139900A1 (en) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Benzamide compounds |
| US11420968B2 (en) | 2018-04-29 | 2022-08-23 | Beigene, Ltd. | Bcl-2 inhibitors |
| CA3224945C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| JP7142173B2 (ja) * | 2019-12-06 | 2022-09-26 | ロクソ オンコロジー， インコーポレイテッド | ブルトン型チロシンキナーゼ阻害剤の投薬 |
-
2020
- 2020-12-03 JP JP2021557408A patent/JP7142173B2/ja active Active
- 2020-12-03 EP EP20825385.6A patent/EP4069219A1/en active Pending
- 2020-12-03 IL IL292882A patent/IL292882A/en unknown
- 2020-12-03 KR KR1020237028538A patent/KR20230127372A/ko active Pending
- 2020-12-03 WO PCT/US2020/063089 patent/WO2021113497A1/en not_active Ceased
- 2020-12-03 AU AU2020397034A patent/AU2020397034B2/en active Active
- 2020-12-03 MX MX2022006631A patent/MX2022006631A/es unknown
- 2020-12-03 CN CN202080095816.0A patent/CN115175677A/zh active Pending
- 2020-12-03 US US17/782,758 patent/US20230041515A1/en active Pending
- 2020-12-03 KR KR1020227022407A patent/KR20220100992A/ko not_active Ceased
- 2020-12-03 BR BR112022009716A patent/BR112022009716A2/pt unknown
-
2022
- 2022-09-12 JP JP2022144243A patent/JP7654604B2/ja active Active
-
2024
- 2024-02-26 AU AU2024201263A patent/AU2024201263B2/en active Active
-
2025
- 2025-03-19 JP JP2025044178A patent/JP2025098099A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021113497A1 (en) | 2021-06-10 |
| JP2025098099A (ja) | 2025-07-01 |
| AU2020397034B2 (en) | 2023-12-07 |
| US20230041515A1 (en) | 2023-02-09 |
| JP2022518974A (ja) | 2022-03-17 |
| JP2022177119A (ja) | 2022-11-30 |
| CN115175677A (zh) | 2022-10-11 |
| AU2024201263A1 (en) | 2024-03-14 |
| BR112022009716A2 (pt) | 2022-08-09 |
| EP4069219A1 (en) | 2022-10-12 |
| NZ788615A (en) | 2024-10-25 |
| JP7142173B2 (ja) | 2022-09-26 |
| JP7654604B2 (ja) | 2025-04-01 |
| KR20220100992A (ko) | 2022-07-18 |
| CA3160417A1 (en) | 2021-06-10 |
| KR20230127372A (ko) | 2023-08-31 |
| AU2020397034A1 (en) | 2022-07-21 |
| MX2022006631A (es) | 2022-09-07 |
| AU2024201263B2 (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200368235A1 (en) | Ibrutinib combination therapy | |
| US8492383B2 (en) | Combination of a nitrogen mustard analogue and imatinib for treatment of chronic lymphocytic leukemia | |
| EP3010505A1 (en) | Pharmaceutical combinations | |
| AU2019201169A1 (en) | Pim kinase inhibitor combinations | |
| CN114901265A (zh) | 用于癌症治疗的btk抑制剂和mdm2抑制剂的组合 | |
| TW201922256A (zh) | 治療淋巴樣惡性疾病之方法 | |
| IL292882A (en) | Dosage of Bruton's tyrosine kinase inhibitor | |
| AU2014279721A1 (en) | Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent | |
| US20150051236A1 (en) | Combinations Useful for the Treatment of Chronic Lymphocytic Leukemia | |
| JP2022177119A5 (enExample) | ||
| KR20240021871A (ko) | 골수증식성 신생물과 연관된 증상의 치료 | |
| EP1496908B1 (en) | Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer | |
| NZ788615B2 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| JP2024513260A (ja) | 骨髄癌処置のためのｌｓｄ１阻害剤の組み合わせ | |
| JP2025538876A (ja) | がん治療のためのｌｓｄ１阻害薬とメニン阻害薬の組合せ | |
| AU2023390908A1 (en) | Methods of treating myeloproliferative neoplasms | |
| US20230390278A1 (en) | Synergistic combinations of valprooic acid and quinacrine | |
| HK40032432A (en) | Ibrutinib combination therapy | |
| WO2018074409A1 (ja) | 慢性骨髄性白血病を治療又は寛解するための医薬組成物 | |
| US20130150375A1 (en) | GEPIRONE-ER TREATMENT OF MAJOR DEPRESSION IN PATIENTS TAKING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) |